Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15007386 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Duensing A, et al. (2004) Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23, 3999-4006 15007386
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease

Y703-p - Kit (human)
Orthologous residues
Kit (human): Y703‑p, Kit (mouse): Y706‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease
Associated Diseases
Diseases: Alterations: Comments:
GIST increased

Y721-p - Kit (human)
Orthologous residues
Kit (human): Y721‑p, Kit (mouse): Y723‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease
Associated Diseases
Diseases: Alterations: Comments:
GIST increased

T412-p - p70S6K (human)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease

T444-p - p70S6K (human)
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease

S447-p - p70S6K (human)
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF increase
imatinib decrease

Y701-p - STAT1 (human)
Orthologous residues
STAT1 (human): Y701‑p, STAT1 (mouse): Y701‑p, STAT1 (rat): Y701‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF no change compared to control
imatinib no change compared to control

Y705-p - STAT3 (human)
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF no change compared to control
imatinib no change compared to control

Y694-p - STAT5A (human)
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  gastric cancer, GIST, small intestine cancer
 Relevant cell lines - cell types - tissues:  GIST544 (gastric), GIST882 (gastric)
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SCF no change compared to control
imatinib no change compared to control


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.